PepGen (NASDAQ:PEPG) Stock Rating Upgraded by Bank of America

PepGen (NASDAQ:PEPG) was upgraded by investment analysts at Bank of America from an “underperform” rating to a “neutral” rating in a note issued to investors on Tuesday, Marketbeat reports. The firm presently has a $6.00 target price on the stock. Bank of America‘s price target would indicate a potential upside of 30.29% from the company’s current price.

Several other research analysts have also issued reports on the stock. HC Wainwright restated a “buy” rating on shares of PepGen in a report on Wednesday, September 9th. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings raised shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.50.

PepGen Stock Performance

Shares of PEPG traded up $2.21 during mid-day trading on Tuesday, reaching $4.61. 101,187,768 shares of the company were exchanged, compared to its average volume of 1,489,272. PepGen has a 52 week low of $1.31 and a 52 week high of $7.80. The stock has a market capitalization of $318.94 million, a PE ratio of -3.52 and a beta of 2.02. The business has a 50 day simple moving average of $2.66 and a two-hundred day simple moving average of $2.98.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). On average, analysts predict that PepGen will post -1.11 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brendel Financial Advisors LLC bought a new position in shares of PepGen during the 3rd quarter worth about $306,000. Squarepoint Ops LLC grew its stake in shares of PepGen by 260.9% in the 2nd quarter. Squarepoint Ops LLC now owns 529,083 shares of the company’s stock valued at $952,000 after buying an additional 382,487 shares during the period. Artia Global Partners LP bought a new stake in PepGen in the 2nd quarter valued at about $370,000. AWM Investment Company Inc. bought a new stake in PepGen in the 2nd quarter valued at about $1,080,000. Finally, ADAR1 Capital Management LLC bought a new stake in PepGen in the 2nd quarter valued at about $4,664,000. 58.01% of the stock is owned by institutional investors.

Key Headlines Impacting PepGen

Here are the key news stories impacting PepGen this week:

• Positive Sentiment: In the FREEDOM2-DM1 study, the 10 mg/kg dose showed the highest reported level of splicing correction and improvements across multiple functional measures. Investors reacted to the potential of the treatment’s mid-stage data. PepGen Phase 2 results
• Positive Sentiment: The clinical news drew unusually heavy trading, with reports noting volume far above typical levels as PepGen stock surged. Benzinga report on PepGen trading
• Neutral Sentiment: Put-option trading rose sharply, with 8,402 puts purchased versus a typical daily volume of 396. This may reflect hedging or bearish positioning, but does not establish the direction of future share performance.
• Negative Sentiment: PepGen reported a quarterly loss of $0.28 per share, one cent wider than the consensus estimate of a $0.27 loss. The small miss may weigh on sentiment, though it was overshadowed by the trial update. PepGen third-quarter results

About PepGen

PepGen Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing. PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.